Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Cohn

Showing results (471-480 of 612) with videos related to

Pageof 62
Sort By:
Inorganic Chemistry|August 3, 2005
Diosmium(III) compounds supported by 2-anilinopyridinate and novel alkynyl derivativesYan-Hui Shi, Wei-Zhong Chen, Kevin D John, et al.
The Lancet. Child & Adolescent Health|January 30, 2018
Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trialPedro A de Alarcon, Katherine K Matthay, Wendy B London, et al.
The New England Journal of Medicine|June 6, 1998
Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance SurveillanceA Pablos-Méndez, M C Raviglione, A Laszlo, et al.
Nature Human Behaviour|May 20, 2020
Mapping global variation in human mobilityMoritz U G Kraemer, Adam Sadilek, Qian Zhang, et al.
The Oncologist|September 28, 2012
Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort studyJohanna C Bendell, Tanios S Bekaii-Saab, Allen L Cohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidyRochelle Bagatell, Pavlina Rumcheva, Wendy B London, et al.
Neoplasia (New York, N.Y.)|August 10, 2000
Lack of homozygously inactivated p73 in single-copy MYCN primary neuroblastomas and neuroblastoma cell linesX T Kong, V A Valentine, S T Rowe, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|April 3, 1998
Size and duration of zidovudine benefit in 1003 HIV-infected patients: U.S. Army, Navy, and Air Force natural history data. Military Medical Consortium for Applied Retroviral ResearchL I Gardner, S H Harrison, C W Hendrix, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 13, 2005
Factors that complicate the treatment of tuberculosis in HIV-infected patientsMark S Dworkin, Michael R Adams, David L Cohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2005
Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology GroupW B London, R P Castleberry, K K Matthay, et al.
Pageof 62

Showing results (471-480 of 612) with videos related to

Sort By:
Pageof 62
Inorganic Chemistry|August 3, 2005
Diosmium(III) compounds supported by 2-anilinopyridinate and novel alkynyl derivativesYan-Hui Shi, Wei-Zhong Chen, Kevin D John, et al.
The Lancet. Child & Adolescent Health|January 30, 2018
Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trialPedro A de Alarcon, Katherine K Matthay, Wendy B London, et al.
The New England Journal of Medicine|June 6, 1998
Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance SurveillanceA Pablos-Méndez, M C Raviglione, A Laszlo, et al.
Nature Human Behaviour|May 20, 2020
Mapping global variation in human mobilityMoritz U G Kraemer, Adam Sadilek, Qian Zhang, et al.
The Oncologist|September 28, 2012
Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort studyJohanna C Bendell, Tanios S Bekaii-Saab, Allen L Cohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidyRochelle Bagatell, Pavlina Rumcheva, Wendy B London, et al.
Neoplasia (New York, N.Y.)|August 10, 2000
Lack of homozygously inactivated p73 in single-copy MYCN primary neuroblastomas and neuroblastoma cell linesX T Kong, V A Valentine, S T Rowe, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|April 3, 1998
Size and duration of zidovudine benefit in 1003 HIV-infected patients: U.S. Army, Navy, and Air Force natural history data. Military Medical Consortium for Applied Retroviral ResearchL I Gardner, S H Harrison, C W Hendrix, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 13, 2005
Factors that complicate the treatment of tuberculosis in HIV-infected patientsMark S Dworkin, Michael R Adams, David L Cohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2005
Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology GroupW B London, R P Castleberry, K K Matthay, et al.
Pageof 62